Dossier assessment
Tezepelumab (severe asthma) – Benefit assessment according to § 35a SGB V
Report documents
-
Extract of dossier assessment
Tezepelumab (severe asthma) – Benefit assessment according to § 35a SGB V
-
Dossier assessment
Tezepelumab (severe asthma) – Benefit assessment according to § 35a SGB V
Dossier assessment
Patients with severe asthma who are inadequately controlled despite high dose inhaled corticosteroids plus another medicinal product for maintenance treatment
- Adolescents aged 12 to 17 years: added benefit not proven
- Adults: added benefit not proven
Project details
- Project no.
- A22-122
- Commission
- Commission awarded on 15.11.2022 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Airways and respiratory system
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
The current version 1.1 of the dossier assessment replaces version 1.0 published on 2023-02-15.
Connected Projects
-
Dossier assessment
Tezepelumab (chronic rhinosinusitis with nasal polyps) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed